Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases

被引:0
|
作者
De Nardo, Laura [1 ,2 ]
Santi, Sara [3 ]
Dalla Pieta, Anna [3 ]
Ferro-Flores, Guillermina [4 ]
Azorin-Vega, Erika [4 ]
Nascimbene, Emma [5 ]
Barbieri, Vito [3 ]
Zorz, Alessandra [6 ]
Rosato, Antonio [3 ,5 ]
Melendez-Alafort, Laura [5 ]
机构
[1] Univ Padua, Dept Phys & Astron, Via Marzolo 8, I-35131 Padua, Italy
[2] INFN Padua, Natl Inst Nucl Phys, Via Marzolo 8, I-35131 Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Gattamelata 64, I-35128 Padua, Italy
[4] Natl Inst Nucl Res ININ, Dept Radioact Mat, Carretera Mex-Toluca S-N, La Marquesa 52750, Ocoyoacac, Mexico
[5] IRCCS, Veneto Inst Oncol IOV, Immunol & Diagnost Mol Oncol Unit, Via Gattamelata 64, I-35128 Padua, Italy
[6] IRCCS, Veneto Inst Oncol IOV, Med Phys Dept, Via Gattamelata 64, I-35128 Padua, Italy
来源
EJNMMI PHYSICS | 2024年 / 11卷 / 01期
关键词
Theranostics; Tb-161; Cell dosimetry; Targeted radionuclide therapy; Somatostatin analogs; Radiopharmaceuticals; Lu-177; S VALUES; RADIONUCLIDES;
D O I
10.1186/s40658-024-00696-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background:<bold> </bold>Lu-177-based radiopharmaceuticals (RPs) are the most used for targeted radionuclide therapy (TRT) due to their good response rates. However, the worldwide availability of Lu-177 is limited. Tb-161 represents a potential alternative for TRT, as it emits photons for SPECT imaging, beta(-)-particles for therapy, and also releases a significant yield of internal conversion (IE) and Auger electrons (AE). This research aimed to evaluate cell dosimetry with the MIRDcell code considering a realistic localization of three Tb-161- and Lu-177-somatostatin (SST) analogs in different subcellular regions as reported in the literature, various cell cluster sizes (25-1000 mu m of radius) and percentage of labeled cells. Experimental values of the alpha- and beta-survival coefficients determined by external beam photon irradiation were used to estimate the survival fraction (SF) of AR42J pancreatic cell clusters and micrometastases. Results:<bold> </bold>The different localization of RPs labeled with the same radionuclide within the cells, resulted in only slight variations in the dose absorbed by the nuclei (AD(N)) of the labeled cells with no differences observed in either the unlabeled cells or the SF. AD(N) of labeled cells (MDLC) produced by Tb-161-RPs were from 2.8-3.7 times higher than those delivered by Lu-177-RPs in cell clusters with a radius lower than 0.1 mm and 10% of labeled cells, due to the higher amount of energy emitted by Tb-161-disintegration in form of IE and AE. However, the Tb-161-RPs/Lu-177-RPs MDLC ratio decreased below 1.6 in larger cell clusters (0.5-1 mm) with > 40% labeled cells, due to the significantly higher Lu-177-RPs cross-irradiation contribution. Using a fixed number of disintegrations, SFs of Tb-161-RPs in clusters with > 40% labeled cells were lower than those of Lu-177-RPs, but when the same amount of emitted energy was used no significant differences in SF were observed between Lu-177- and Tb-161-RPs, except for the smallest cluster sizes. Conclusions:<bold> </bold>Despite the emissions of IE and AE from Tb-161-RPs, their localization within different subcellular regions exerted a negligible influence on the AD(N). The same cell damage produced by Lu-177-RPs could be achieved using smaller quantities of Tb-161-RPs, thus making Tb-161 a suitable alternative for TRT.
引用
收藏
页数:24
相关论文
共 15 条
  • [1] Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
    Alcocer-Avila, Mario E.
    Ferreira, Aymeric
    Quinto, Michele A.
    Morgat, Clement
    Hindie, Elif
    Champion, Christophe
    EJNMMI PHYSICS, 2020, 7 (01)
  • [2] Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
    Mario E. Alcocer-Ávila
    Aymeric Ferreira
    Michele A. Quinto
    Clément Morgat
    Elif Hindié
    Christophe Champion
    EJNMMI Physics, 7
  • [3] Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
    Abdlkadir, Ahmed Saad
    Abufara, Alaa
    Al-Ibraheem, Akram
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 58 (06) : 381 - 382
  • [4] Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
    Mueller, Cristina
    Reber, Josefine
    Haller, Stephanie
    Dorrer, Holger
    Bernhardt, Peter
    Zhernosekov, Konstantin
    Tuerler, Andreas
    Schibli, Roger
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (03) : 476 - 485
  • [5] Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
    Cristina Müller
    Josefine Reber
    Stephanie Haller
    Holger Dorrer
    Peter Bernhardt
    Konstantin Zhernosekov
    Andreas Türler
    Roger Schibli
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 476 - 485
  • [6] Development of a skin dosimetry model for assessing normal tissue dosimetry following CD44v6 therapy: a comparison between 177Lu and 161Tb
    Hemmingsson, J.
    Nestor, M.
    Mortensen, A. Lundgren
    Svensson, J.
    Bernhardt, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S207 - S207
  • [7] Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
    Hindie, Elif
    Zanotti-Fregonara, Paolo
    Quinto, Michele A.
    Morgat, Clement
    Champion, Christophe
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (05) : 759 - 764
  • [8] [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617
    Schaefer-Schuler, Andrea
    Burgard, Caroline
    Blickle, Arne
    Maus, Stephan
    Petrescu, Christine
    Petto, Sven
    Bartholomae, Mark
    Stemler, Tobias
    Ezziddin, Samer
    Rosar, Florian
    THERANOSTICS, 2024, 14 (05): : 1829 - 1840
  • [9] Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure (vol 58, pg 381, 2024)
    Abdlkadir, Ahmed Saad
    Abufara, Alaa
    Al-Ibraheem, Akram
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 59 (01) : 94 - 94
  • [10] First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
    Chirindel, Alin
    Nicolas, Guillaume P.
    Westerbergh, Frida
    Mcdougall, Lisa
    Schmid, David E.
    Geistlich, Susanne
    Tschan, Viviane J.
    Busslinger, Sarah D.
    Fokkema, Angelique
    Aceto, Nicola
    Bernhardt, Peter
    van der Meulen, Nicholas P.
    Muller, Cristina
    Wild, Damian
    Schibli, Roger
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 52 (05) : 1628 - 1630